Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Astrocytes and microglia are central players in a myriad of processes in the healthy and
diseased brain, ranging from metabolism to immunity. The crosstalk between these two cell …

Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-
brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport …

Synapse dysfunction and loss are hallmarks of neurodegenerative diseases that correlate
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Therapeutic antibody drug development is a rapidly growing sector of the pharmaceutical
industry. However, antibody drug development for the brain is a technical challenge, and …

Alzheimer's disease (AD) is the major cause of dementia that is now threatening the lives of
billions of elderly people on the globe, and recent progress in the elucidation of the …

Alzheimer disease (AD) is the most common neurodegenerative disease, and with no
efficient curative treatment available, its medical, social, and economic burdens are …

Despite extensive research, no disease-modifying therapeutic option, able to prevent, cure
or halt the progression of Alzheimer's disease [AD], is currently available. AD, a devastating …

The association between dysfunctional microglia and amyloid-β (Aβ) is a fundamental
pathological event and increases the speed of Alzheimer's disease (AD). Additionally, the …